Related Experiment Video
Updated: Jul 5, 2026
Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
Published on: March 31, 2015
Defining function of wild-type and three patient-specific TP53 mutations in a zebrafish model of embryonal
Jiangfei Chen1,2, Kunal Baxi2,3, Amanda E Lipsitt2,4
1Institute of Environmental Safety and Human Health, Wenzhou Medical University, Wenzhou, China.
Abstract:
In embryonal rhabdomyosarcoma (ERMS) and generally in sarcomas, the role of wild-type and loss- or gain-of-function TP53 mutations remains largely undefined. Eliminating mutant or restoring wild-type p53 is challenging; nevertheless, understanding p53 variant effects on tumorigenesis remains central to realizing better treatment outcomes. In ERMS, >70% of patients retain wild-type TP53, yet mutations when present are associated with worse prognosis. Employing a kRAS-driven ERMS tumor model and tp53 null (tp53-/-) zebrafish, we define wild-type and patient-specific TP53 mutant effects on tumorigenesis. We demonstrate that tp53 is a major suppressor of tumorigenesis, where tp53 loss expands tumor initiation from <35% to >97% of animals. Characterizing three patient-specific alleles reveals that TP53 partially retains wild-type p53 apoptotic activity that can be exploited, whereas TP53 and TP53 encode two structurally related proteins with gain-of-function effects that predispose to head musculature ERMS. TP53 unexpectedly also predisposes to hedgehog-expressing medulloblastomas in the kRAS-driven ERMS-model.
Insights
TP53 mutations impact embryonal rhabdomyosarcoma (ERMS) development. Understanding TP53 variants is crucial for ERMS treatment, as some mutations promote tumor growth and others retain tumor-suppressing functions.
Area of Science:
- Oncology
- Genetics
- Developmental Biology
Background:
- The role of TP53 mutations in sarcomas, including embryonal rhabdomyosarcoma (ERMS), is not well understood.
- While most ERMS patients retain wild-type TP53, mutations are linked to poorer prognoses.
Purpose of the Study:
- To investigate the effects of wild-type and patient-specific TP53 mutations on ERMS tumorigenesis.
- To explore therapeutic strategies by understanding how TP53 variants influence tumor initiation and progression.
Main Methods:
- Utilized a kRAS-driven ERMS zebrafish model with tp53 null (tp53-/-) and wild-type TP53.
- Analyzed three patient-specific TP53 mutant alleles for their impact on tumorigenesis and apoptosis.
Main Results:
- TP53 loss significantly increases ERMS tumor initiation from <35% to >97% in zebrafish.
- Certain TP53 alleles retain partial wild-type apoptotic activity, suggesting potential therapeutic targets.
- Specific TP53 gain-of-function mutations predispose to head musculature ERMS and hedgehog-expressing medulloblastomas.
Conclusions:
- TP53 acts as a major tumor suppressor in ERMS.
- Patient-specific TP53 mutations have diverse effects, with some offering therapeutic potential and others promoting aggressive tumor phenotypes.
- Understanding TP53 variant functions is critical for developing targeted therapies for ERMS and related sarcomas.
More Related Videos
09:39Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
Published on: December 26, 2014
09:43Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
Published on: May 17, 2017
